53Biologics Awarded Best Company in Biotechnology Innovation at Farmaforum

This award acknowledges the company’s groundbreaking work in microbial expression systems and its ongoing commitment to delivering cutting-edge biotechnological solutions for the global market.

53Biologics, a Contract Development and Manufacturing Organization (CDMO) headquartered in Valladolid, Spain, has been awarded the prestigious Biotechforum Award for "Best Company in Biotechnology Innovation" during Farmaforum, Spain’s most prominent pharmaceutical and biotech industry event. The award highlights the company’s commitment to innovative bioprocesses and biotechnological developments, particularly in microbial expression systems.

The recognition comes after years of consistent growth and success. The company was founded by a group of scientists believing that biologics would shape the future of the pharmaceutical industry. From day one, the commitment of the company’s employees has been a driving force behind 53Biologics’ success and mission to become a leader among CDMOs.

The company’s CEO, Pablo Gutiérrez, expressed his pride at receiving the award: "This recognition at Farmaforum validates the hard work and innovation our team has put into every project. It’s an honor to be acknowledged by such a prestigious event, and it inspires us to continue pushing the boundaries in giving the best and most innovative CDMO services to support pharma and biotech companies. We thank everyone who supported us through their votes.” Gutiérrez also added “This award is not just an award; it’s a responsibility. It reaffirms that we’re on the right path, delivering quality and effective solutions to the biopharmaceutical industry,”.

Gutiérrez emphasized that 53Biologics currently operates over 4500 square meters of cutting-edge facilities, including its cGMP production lines equipped with the latest single-use technologies to offer flexible manufacturing capacities and reduced turnaround times. In addition, the company expanded its capacity with a new GMP microbial manufacturing line, featuring a 2000L fermenter, this year. This expansion reflects the growing global interest in microbial-based products and positions 53Biologics to meet international demand.

The company is known for providing end-to-end support at all stages of their drug development, from R&D to commercial manufacturing. Its CEO remarked that since its inception, 53Biologics have multiplied by six its workforce, that nowadays they generate multi-million-euro revenues and the commitment to maintain this growth rates in the upcoming five years. With this award, 53Biologics is recognized as a leader in biotechnology innovation and remains dedicated to decoding biologics production, enabling their customers to bring new therapies to patients faster and more efficiently.

About 53Biologics:

53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.

For more information about the company and its services, please visit 53Biologics.com or contact the 53Biologics’ team through info@53biologics.com